A shot that could shield healthcare workers from a silent killer
NCT ID NCT04072211
First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time
Summary
This trial tests whether a three-dose hepatitis B vaccine can protect healthcare workers in Zambia from infection. The vaccine is given at 0, 1, and 6 months, and blood tests measure the immune response. The goal is to see if the vaccine produces protective antibodies and cellular immunity in this high-risk group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Hepatitis B vaccine (Engerix-B)
- What this could lead to
- If successful, this could show that vaccinating healthcare workers in high-risk areas effectively prevents hepatitis B infection, potentially reducing disease spread.
- What could go wrong
- The trial is a demonstration project, so it may not prove long-term protection. Some people may not develop adequate immunity, and the vaccine can cause mild side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTH CARE ASSOCIATED INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Kalulushi district all facilities
Kalulushi, Copperbelt, 10101, Zambia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple wipe slash hospital infections?
- Hepatitis b mutations linked to higher virus levels
- Scientists probe immune cell exhaustion in hepatitis b
- New protocol aims to slash brain drain infections in ICUs
- New antibody shot aimed at taming hepatitis b
- New study explores Kidney-Friendly hepatitis b drug for transplant patients